Our World

Brazil

Egypt

Europe

Hong Kong

Malaysia

Mexico

Morocco

Philippines

Saudi Arabia

South Africa

Taiwan

Thailand

Tunisia

Turkey

UAE

USA

Vietnam

Canada

Global HQ
Contact Us
Biocon Biocologics Logo
  • About Us
    • Overview
    • Our Business
    • Board of Directors
    • Executive Committee
    • Scientific Publications
    • Awards & Recognition
    • Our Legacy
  • Products
    • Overview
    • Product Locator
  • Business
    • Overview
    • Global Biosimilars Portfolio
    • Global Footprint
    • Partners
    • Emerging Markets
    • Biocon Biologics U.S.
    • Biocon Biologics EU
    • Biocon Biologics in Canada
  • Capabilities
    • Research & Development
    • Quality & Compliance
    • Global Scale Manufacturing
      • India
      • Malaysia
  • Commitment
    • Overview
    • EHS Certifications
  • News
    • Overview
    • Company Statements
    • Stories
    • Media Stories
    • Media Contacts
    • Video Gallery
    • Resource Center
  • Careers
    • Working With Us
    • Now Hiring
  • Stories
    • Overview
    • Brand Stories
    • Patients’ Stories
    • Employee Stories
Site Logo

Biocon Q2FY18 Revenues at Rs 1019 Crore; EBITDA at Rs 233 Crore; Net Profit at Rs 69 Crore

  • Thu, 26-Oct-2017
  • Posted by: Biocon Biologics
No Comments

Biocon Ranked Among Top 10 Global Pharma & Biotech Employers

  • Wed, 25-Oct-2017
  • Posted by: Biocon Biologics
No Comments

US FDA Issues Complete Response Letter for Proposed Biosimilar Pegfilgrastim

  • Tue, 10-Oct-2017
  • Posted by: Biocon Biologics
No Comments

Biocon’s Insulins facility in Malaysia Receives EU GMP Compliance Certificate

  • Thu, 07-Sep-2017
  • Posted by: Biocon Biologics
No Comments

JDRF Supports Biocon Study of Novel, Fast-acting Oral Insulin Tregopil for Type 1 Diabetes Treatment

  • Wed, 06-Sep-2017
  • Posted by: Biocon Biologics
No Comments

USFDA Target Action Date for Trastuzumab reset to December 3, 2017

  • Wed, 30-Aug-2017
  • Posted by: Biocon Biologics
No Comments

Status of EMA Dossiers

  • Wed, 16-Aug-2017
  • Posted by: Biocon Biologics
No Comments

USFDA visit in May/June 2017

  • Thu, 03-Aug-2017
  • Posted by: Biocon Biologics
No Comments

Biocon Reports Q1FY18 Revenue at Rs 988 Crore; EBITDA at Rs 246 Crore; Net Profit at Rs 81 Crore

  • Thu, 27-Jul-2017
  • Posted by: Biocon Biologics
No Comments

FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon’s Proposed Biosimilar Trastuzumab

  • Fri, 14-Jul-2017
  • Posted by: Biocon Biologics
No Comments
  • 1
  • …
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30

Quick Links

  • About Us
  • News
  • Our Stories
  • Biocon Limited
  • Syngene
  • Biocon Foundation
  • Biocon Academy

Business

  • U.S.
  • Europe

RECOMMENDED SITES

  • Science Gallery
  • ABLE
  • Immuneel Therapeutics
  • Bicara Therapeutics
  • Equillium
  • Biocon Blog

Get in Touch

  • Contact Us
  • Sitemap
Report adverse events/side effects/product complaints and/or to submit medical inquiries for Biocon Biologics Limited & BBL Affiliate products.

* Cookie Policy | Privacy Policy | Terms of Use © 2026, Biocon Biologics Limited (a Subsidiary of Biocon Limited). All Rights Reserved
Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics U.S. Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>
Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics EU Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>
Leaving the Biocon Biologics site

You are now leaving the Biocon Biologics page for a Biocon Biologics affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>
Our Spring Sale Has Started

You can see how this popup was set up in our step-by-step guide: https://wppopupmaker.com/guides/auto-opening-announcement-popups/